Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure - Full Text View

Purpose

The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success.

Condition	Intervention	Phase
HIV Infections	Drug: Lopinavir/Ritonavir Drug: Ritonavir Drug: GW433908	Phase III

MedlinePlus related topics:

AIDS AIDS Medicines

Drug Information available for:

Ritonavir Lopinavir Fosamprenavir Fosamprenavir calcium Fosamprenavir sodium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Parallel Assignment, Safety Study

Official Title:	A Phase III, Randomized, Multicenter, Parallel Group, Open-Label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/Ritonavir (700mg/100mg Twice Daily or 1400mg/200mg Once Daily) Versus Lopinavir/Ritonavir (400mg/100mg Twice Daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment:	330
Study Start Date:	May 2001

Detailed Description:

Patients will receive 2 dosing regimens of GW433908/RTV or LPV/RTV, in combination with 2 active RTIs, after failing their first or second protease inhibitor-containing regimen. Patients are required to be on therapy at time of screening and must remain on this therapy until Day 1.

Eligibility

Ages Eligible for Study:	13 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

Have a viral load of 1,000 or more copies/ml.
Have taken protease inhibitors (PIs).
Have taken PI drugs for at least 12 straight weeks and have had virologic failure on the PIs.
Are now taking antiretroviral therapy.
Are male or female and are at least 13 years old (or 18 if local requirement) and can provide consent from parent or guardian if under 18.
Are females unable to have children or, if are able to have children, are not pregnant and agree to use approved birth control.

Exclusion Criteria

Patients will not be eligible for this study if they:

Have taken APV or LPV for more than 1 week.
Have taken tenofovir disoproxil fumarate (TDF) or adefovir.
Have taken more than 2 PIs.
Are unable to take 2 active RTIs, as specified by the study.
Have an active CDC Category C disease.
Have certain abnormal laboratory tests.
Are pregnant or breast-feeding.
Have a serious health problem (e.g., diabetes, heart problems, hepatitis) that might risk the safety of the patient.
Have a history of significant kidney or bone disease.
Are not able to take drugs by mouth and cannot absorb them.
Have had pancreatitis or hepatitis within the previous 6 months.
Have a drug allergy or other allergy which might cause a problem during the study.
Have had radiation or chemotherapy within 28 days of taking the study drug, or expect to need these during the study.
Have taken drugs that affect the immune system (corticosteroids, interleukins, interferons) or drugs with anti-HIV activity (hydroxyurea or foscarnet) within 28 days prior to taking the study drug.
Have had any HIV vaccine within 3 months before taking the study drug.
Have taken certain other drugs within 28 days prior to taking the study drug, or expect to need them during the study.
Use alcohol or illicit drugs in a way that the doctor feels would interfere with the study.
Are not able to take the study drugs.
Have inadequate kidney function.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00025727

Show 32 Study Locations

Sponsors and Collaborators

GlaxoSmithKline

More Information

Study ID Numbers:	316C
First Received:	October 15, 2001
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00025727
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

HIV-1

HIV Protease Inhibitors

Ritonavir

RNA, Viral

Anti-HIV Agents

Viral Load

ABT 378

VX-175

Study placed in the following topic categories:

Virus Diseases

Sexually Transmitted Diseases, Viral

Fosamprenavir

Lopinavir

Ritonavir

HIV Infections

Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome

Retroviridae Infections

Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

Anti-Infective Agents

RNA Virus Infections

HIV Protease Inhibitors

Slow Virus Diseases

Anti-HIV Agents

Immune System Diseases

Molecular Mechanisms of Pharmacological Action

Enzyme Inhibitors

Infection

Antiviral Agents

Pharmacologic Actions

Protease Inhibitors

Anti-Retroviral Agents

Therapeutic Uses

Lentivirus Infections

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	GlaxoSmithKline
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00025727